GW’s Cannabis-Based Epilepsy Drug Set For European Approval
Cannabis Law Report
JULY 30, 2019
Following an encouraging initial US launch, GW Pharmaceuticals’s cannabidiol oral solution is also set to achieve European approval later in 2019. GW Pharmaceuticals said in May, Epidiolex was successful in treating seizures in patients with a rare form of childhood epilepsy called tuberous sclerosis complex during a late-stage trial.
Let's personalize your content